| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Priscilla M. Clarkson | Q110286889 |
| P2093 | author name string | Paul D Thompson | |
| Richard H Karas | |||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1681-1690 | |
| P577 | publication date | 2003-04-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Statin-associated myopathy. | |
| P478 | volume | 289 |
| Q35901470 | A Case of Docetaxel Induced Myositis and Review of the Literature |
| Q51067287 | A Drug Screen using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a Potential Treatment for Hypercholesterolemia. |
| Q37341027 | A Peculiar Formula of Essential Amino Acids Prevents Rosuvastatin Myopathy in Mice. |
| Q88766431 | A comprehensive review and meta-analysis of risk factors for statin-induced myopathy |
| Q50526524 | A new mitochondria-related disease showing myopathy with episodic hyper-creatine kinase-emia. |
| Q43716006 | A pain in the arms |
| Q92575247 | A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents |
| Q39948282 | A proposal for a pharmacokinetic interaction significance classification system (PISCS) based on predicted drug exposure changes and its potential application to alert classifications in product labelling |
| Q33937142 | A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design |
| Q36899354 | A randomized trial of coenzyme Q10 in patients with statin myopathy: rationale and study design |
| Q38113494 | A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs |
| Q36011053 | A review of time courses and predictors of lipid changes with fenofibric acid-statin combination |
| Q47247595 | A simple assay for the simultaneous determination of rosuvastatin acid, rosuvastatin-5S-lactone, and N-desmethyl rosuvastatin in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS). |
| Q43190391 | A simple endocrinological cause of a complex cardiovascular picture. |
| Q35223789 | A small-molecule screening strategy to identify suppressors of statin myopathy |
| Q46611139 | A three-part study to investigate the incidence and potential etiologies of tadalafil-associated back pain or myalgia |
| Q37310467 | A viewpoint on statin effects − benefits and problems |
| Q35799847 | ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis |
| Q45993642 | ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. |
| Q36462041 | AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. |
| Q41082961 | ANMCO Position Paper: diagnostic-therapeutic pathway in patients with hypercholesterolaemia and statin intolerance |
| Q35585945 | Achievement of low-density lipoprotein cholesterol goals: new strategies to address new guidelines |
| Q34397571 | Acute exacerbation of previously undiagnosed chronic focal myositis in an Aboriginal patient on maintenance haemodialysis |
| Q35962023 | Acute rhabdomyolysis associated with ofloxacin/levofloxacin therapy |
| Q36872923 | Acute-onset rhabdomyolysis secondary to sitagliptin and atorvastatin interaction |
| Q35918848 | Addressing cardiovascular risk beyond low-density lipoprotein cholesterol: the high-density lipoprotein cholesterol story |
| Q38207488 | Addressing statin adverse effects in the clinic: the 5 Ms. |
| Q47360791 | Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility Analysis. |
| Q36007848 | Advances in diabetes for the millennium: diabetes and cholesterol |
| Q36384708 | Advances in understanding drug-induced neuropathies |
| Q30823700 | Alterations in zebrafish development induced by simvastatin: Comprehensive morphological and physiological study, focusing on muscle. |
| Q37730479 | Alternate Day versus Once Daily Atorvastatin for Primary Prevention of (CHD) in Naïve Patients of Dyslipidemia |
| Q57314076 | Amiodarone Interacts with Simvastatin but not with Pravastatin Disposition Kinetics |
| Q89667627 | An in vivo brain-bacteria interface: the developing brain as a key regulator of innate immunity |
| Q50102993 | Analysis of SLCO1B1 and APOE genetic polymorphisms in a large ethnic Hakka population in southern China. |
| Q33508676 | Anticipating the evolution of clinical cholesterol guidelines: implications of recent statin intervention trials |
| Q33846255 | Applied pharmacogenomics in cardiovascular medicine |
| Q35580946 | Are Statins Indicated for the Primary Prevention of Coronary Heart Disease in Octogenarians? Protagonist Viewpoint |
| Q40417355 | Are patients undergoing treatment of hyperlipidaemia with statins the best candidates for early cardiac rehabilitation? |
| Q46496531 | Are statin medications safe in patients with ALS? |
| Q36975446 | Assessing appropriateness of lipid management among patients with diabetes mellitus: moving from target to treatment |
| Q50645749 | Assessment of Preclinical Liver and Skeletal Muscle Biomarkers Following Clofibrate Administration in Wistar Rats. |
| Q38021775 | Assessment of low-density lipoprotein targets |
| Q57151967 | Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis |
| Q38613096 | Association between infection and severe drug adverse reactions: an analysis using data from the Japanese Adverse Drug Event Report database. |
| Q24655191 | Association between statin-associated myopathy and skeletal muscle damage |
| Q54373168 | Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. |
| Q89091030 | Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry |
| Q35941695 | Asymptomatic hypothyroidism and statin-induced myopathy |
| Q38102654 | Asymptomatic/pauci-symptomatic creatine kinase elevations (hyperckemia). |
| Q39721147 | Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy |
| Q80033733 | Atorvastatin-induced early-onset rhabdomyolysis in a patient with nephrotic syndrome |
| Q40292972 | Atorvastatin: beyond lipid-lowering effects in the diabetic population |
| Q21092898 | Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians |
| Q36835515 | Benefit/risk ratio of statins in primary prevention |
| Q26853571 | Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes |
| Q36241424 | Berberine Reduces Neurotoxicity Related to Nonalcoholic Steatohepatitis in Rats |
| Q45331013 | Biomarkers of drug-induced skeletal muscle injury in the rat: troponin I and myoglobin |
| Q46253336 | Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy |
| Q64269053 | Body Composition Changes During a 24-h Winter Mountain Running Race Under Extremely Cold Conditions |
| Q21261269 | Breast ductal lavage for biomarker assessment in high risk women: rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placebo |
| Q38120138 | Bringing genome-wide association findings into clinical use. |
| Q37702722 | Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease |
| Q36040739 | Cardiovascular complications of immunosuppressive agents in renal transplant recipients. |
| Q40523453 | Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice |
| Q36536175 | Cholesterol lowering for secondary prevention: what statin dose should we use? |
| Q50856006 | Chronic oral administration of low-dose combination of fenofibrate and rosuvastatin protects the rat heart against experimentally induced acute myocardial infarction. |
| Q40596214 | Ciprofloxacin and statin interaction: a cautionary tale of rhabdomyolysis |
| Q37579733 | Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care |
| Q37230383 | Clinical characterization and molecular mechanisms of statin myopathy |
| Q48203172 | Clinical evaluation of rosuvastatin in heart transplant patients with hypercholesterolemia and therapeutic failure of other statin regimens: short-term and long-term efficacy and safety results. |
| Q90482667 | Clinical features related to statin-associated muscle symptoms |
| Q36426816 | Clinical implications of pharmacogenomics of statin treatment |
| Q36830192 | Clinical pharmacology in the geriatric patient |
| Q54446305 | Coenzyme Q(10) and selenium in statin-associated myopathy treatment. |
| Q49829630 | Coenzyme Q10 Supplementation in Aging and Disease. |
| Q88383581 | Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem |
| Q36869671 | Coenzyme Q10: is there a clinical role and a case for measurement? |
| Q35124717 | Colesevelam HCl: a non-systemic lipidaltering drug |
| Q30434678 | Combination therapy of dyslipidemia in non-insulin-dependent diabetes mellitus and the metabolic syndrome. |
| Q35964012 | Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study |
| Q37875049 | Common sense treatment for common lipid disorders. |
| Q35980419 | Communicating statin evidence to support shared decision-making |
| Q51369965 | Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. |
| Q46000508 | Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. |
| Q37329878 | Compartment syndrome: an unusual complication of influenza A infection. |
| Q33938091 | Correlates of fatigue in patients with heart failure. |
| Q46201338 | Curcumin improves atorvastatin-induced myotoxicity in rats: Histopathological and biochemical evidence. |
| Q38851957 | Cytostatic Effect of Repeated Exposure to Simvastatin: A Mechanism for Chronic Myotoxicity Revealed by the Use of Mesodermal Progenitors Derived from Human Pluripotent Stem Cells. |
| Q43271986 | Decreased ubiquinone availability and impaired mitochondrial cytochrome oxidase activity associated with statin treatment |
| Q46757868 | Decreasing LDL cholesterol and medication cost with every-other-day statin therapy |
| Q54978636 | Delayed presentation of severe rhabdomyolysis leading to acute kidney injury following atorvastatin-gemfibrozil combination therapy: a case report. |
| Q89964334 | Destroy to Rebuild: The Connection Between Bone Tissue Remodeling and Matrix Metalloproteinases |
| Q37807503 | Detecting and treating hyperlipidemia in children with type 1 diabetes mellitus: are standard guidelines applicable to this special population? |
| Q44390514 | Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals |
| Q47255167 | Development and validation of a sensitive, simple, and rapid method for simultaneous quantitation of atorvastatin and its acid and lactone metabolites by liquid chromatography-tandem mass spectrometry (LC-MS/MS). |
| Q93199980 | Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics |
| Q42917105 | Development of a Population Pharmacokinetic Model for Atorvastatin Acid and Its Lactone Metabolite |
| Q84548365 | Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes |
| Q92910068 | Diabetogenic effect of pravastatin is associated with insulin resistance and myotoxicity in hypercholesterolemic mice |
| Q57825140 | Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin |
| Q43258273 | Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin |
| Q46701148 | Differential association between statin exposure and elevated levels of creatine kinase |
| Q48689626 | Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. |
| Q39777310 | Discovery of DF-461, a Potent Squalene Synthase Inhibitor |
| Q88241232 | Do Statins Induce or Protect from Acute Kidney Injury and Chronic Kidney Disease: An Update Review in 2018 |
| Q38072614 | Do the frequencies of adverse events increase, decrease, or stay the same with long-term use of statins? |
| Q35780072 | Do women with statin-related myalgias have low vitamin D levels? |
| Q33776187 | Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia? |
| Q87075754 | Drug interactions in general dental practice--considerations for the dental practitioner |
| Q89104302 | Drug-Induced Rhabdomyolysis Atlas (DIRA) for idiosyncratic adverse drug reaction management |
| Q38177333 | Drug-drug interaction with statins. |
| Q36694584 | Drug-induced musculoskeletal disorders |
| Q93380372 | Dynamic Contrast-Enhanced MRI of OATP Dysfunction in Diabetes |
| Q39985485 | Dyslipidemia in Special Ethnic Populations |
| Q35573543 | Dyslipidemia in special ethnic populations |
| Q42416649 | Editorial: Closing sale of innovative treatment options for the treatment of diabetes and metabolic disorders? |
| Q47342360 | Effect modification by region in the associations of LEP G2548A and LEPR Q223R polymorphisms with statin-induced CK elevation |
| Q36640423 | Effect of Coenzyme Q10 Supplementation in Statin-Treated Obese Rats |
| Q80442031 | Effect of atorvastatin on energy expenditure and skeletal muscle oxidative metabolism at rest and during exercise |
| Q37017426 | Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. |
| Q52931527 | Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. |
| Q54479293 | Effect of simvastatin on passive strain-induced skeletal muscle injury in rats. |
| Q35670282 | Effect of statins on skeletal muscle function |
| Q42484896 | Effect of the Combination of Ezetimibe and Simvastatin on Gluconeogenesis and Oxygen Consumption in the Rat Liver |
| Q93147945 | Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis |
| Q34987299 | Effects of Long-Term Supplementation of Blue-Green Algae on Lipid Metabolism in C57BL/6J mice. |
| Q34173180 | Effects of Statins on Skeletal Muscle: A Perspective for Physical Therapists |
| Q41604256 | Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study |
| Q53131114 | Effects of piperine, cinnamic acid and gallic acid on rosuvastatin pharmacokinetics in rats. |
| Q37177038 | Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people |
| Q29547856 | Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins |
| Q37724381 | Efflux and uptake transporters as determinants of statin response. |
| Q37731858 | Electronic health records for biological sample collection: feasibility study of statin-induced myopathy using the Clinical Practice Research Datalink. |
| Q53668416 | Electronic healthcare databases for active drug safety surveillance: is there enough leverage? |
| Q35600341 | Elevated blood lipids are uncommon in patients with post-polio syndrome--a cross sectional study |
| Q45982016 | Elevated creatine phosphokinase levels associated with linezolid therapy. |
| Q93119620 | Enantiospecific Pharmacogenomics of Fluvastatin |
| Q35736398 | Endothelial protective genes induced by statin are mimicked by ERK5 activation as triggered by a drug combination of FTI-277 and GGTI-298. |
| Q89969634 | Enhanced ER-associated degradation of HMG CoA reductase causes embryonic lethality associated with Ubiad1 deficiency |
| Q40386056 | Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles |
| Q37198943 | Evaluation of adverse effects of lisinopril and rosuvastatin on hematological and biochemical analytes in wistar rats |
| Q36817063 | Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis |
| Q34155702 | Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications |
| Q36832935 | Evolving therapies for multiple sclerosis |
| Q37224520 | Exertional rhabdomyolysis of the bilateral adductor magnus |
| Q38851603 | Expert opinion: the therapeutic challenges faced by statin intolerance |
| Q28481360 | Exploration of the association rules mining technique for the signal detection of adverse drug events in spontaneous reporting systems |
| Q36883366 | Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor |
| Q81461109 | Facts and ideas from anywhere |
| Q60301892 | Fast skeletal troponin I, but not the slow isoform, is increased in patients under statin therapy: a pilot study |
| Q48583485 | Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin. |
| Q37898699 | Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia |
| Q28220294 | Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review |
| Q36366283 | Fibrates in combination with statins in the management of dyslipidemia |
| Q46919305 | Fluvastatin-induced dermatomyositis |
| Q35807245 | Fluvastatin: clinical and safety profile |
| Q36249930 | Fluvastatin: efficacy and safety in reducing cardiac events |
| Q57825157 | Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population |
| Q43004038 | GATM locus does not replicate in rhabdomyolysis study. |
| Q54629680 | Gene expression in skeletal muscle of coronary artery disease patients after concentric and eccentric endurance training. |
| Q33765249 | Genealogical analysis as a new approach for the investigation of drug intolerance heritability |
| Q38009858 | Genetic predisposition to atorvastatin-induced myopathy: a case report |
| Q50054110 | Genetic variation in statin intolerance and a possible protective role for UGT1A1. |
| Q37021351 | Genetics of Dyslipidemia |
| Q57787430 | Geranylgeraniol-induced Myogenic Differentiation of C2C12 Cells |
| Q36649815 | Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl. |
| Q35139244 | Graft vessel disease following heart transplantation: a systematic review of the role of statin therapy |
| Q37331801 | Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes |
| Q37331821 | Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver. |
| Q34527445 | Hepatitis, rhabdomyolysis and multi-organ failure resulting from statin use |
| Q38995188 | High-Intensity Atorvastatin-Induced Rhabdomyolysis in an Elderly Patient With NSTEMI: A Case Report and Review of the Literature |
| Q37350164 | How do you treat patients with myalgia who take statins? |
| Q36623143 | Hypertension and aging |
| Q64905260 | Hypolipidemic Effect of Arthrospira (Spirulina) maxima Supplementation and a Systematic Physical Exercise Program in Overweight and Obese Men: A Double-Blind, Randomized, and Crossover Controlled Trial. |
| Q33207919 | Hypothyroidism and dyslipidemia: modern concepts and approaches |
| Q28710219 | Hypothyroidism complicating nephropathy in a diabetes patient |
| Q43965937 | Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach |
| Q36986507 | Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges |
| Q34037784 | Imaging of zebrafish in vivo with second-harmonic generation reveals shortened sarcomeres associated with myopathy induced by statin |
| Q38619946 | Immune-mediated statin myopathy |
| Q37089806 | In vivo 1D and 2D correlation MR spectroscopy of the soleus muscle at 7T |
| Q34582294 | In vivo anti-hyperlipidemic activity of the triterpene from the stem bark of Protorhus longifolia (Benrh) Engl |
| Q43821019 | Increased autophagy accelerates colchicine-induced muscle toxicity |
| Q28243492 | Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver |
| Q55069249 | Increased dosage of cyclosporine induces myopathy with increased seru creatine kinase in an elderly patient on chronic statin therapy. |
| Q35915932 | Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions |
| Q42706490 | Inflammatory myopathy associated with statins: report of three cases |
| Q36687277 | Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans |
| Q38038125 | Inhibition of cholesterol absorption: targeting the intestine. |
| Q88011581 | Inhibition of proprotein convertase subtilisin/kexin type 9: a novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia |
| Q96955219 | Initial seronegative immune-mediated necrotising myopathy with subsequent anti-HMGCR antibody development and response to rituximab: case report |
| Q40501497 | Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin |
| Q57476139 | Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions |
| Q42698562 | Is there a problem with ezetimibe or just ENHANCEd hype? |
| Q35197114 | Isoprenoid metabolism and the pleiotropic effects of statins |
| Q58362346 | Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017 |
| Q38924930 | Laboratory Medicine in the Clinical Decision Support for Treatment of Hypercholesterolemia: Pharmacogenetics of Statins |
| Q42642838 | Lamivudine Therapy Exacerbates Bilirubinemia in Patients Underlying Severely Advanced Hepatitis |
| Q35185667 | Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people |
| Q46694148 | Lipid lowering drug and other toxic myopathies |
| Q45342111 | Lipid lowering therapy in geriatric patients |
| Q35953069 | Lipid-induced Muscle Insulin Resistance Is Mediated by GGPPS via Modulation of the RhoA/Rho Kinase Signaling Pathway |
| Q37218576 | Lipidomics-based safety biomarkers for lipid-lowering treatments |
| Q34221540 | Lipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle |
| Q35071421 | Liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma |
| Q28167386 | Long-term statin safety and efficacy in secondary prevention: can combination therapy improve outcomes? |
| Q35214678 | Long-term statin treatment in children with familial hypercholesterolemia: more insight into tolerability and adherence |
| Q46187390 | Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients |
| Q36385138 | Low-density lipoprotein reduction: is the risk worth the benefit? |
| Q33743700 | Management of a mixed overdose of calcium channel blockers, β-blockers and statins |
| Q34722828 | Management of dyslipidemia in women in the post-hormone therapy era. |
| Q54603468 | Managing statin-induced muscle toxicity in a lipid clinic. |
| Q34570995 | Mechanisms and assessment of statin-related muscular adverse effects |
| Q35575560 | Mechanisms of statin-induced myalgia assessed by physiogenomic associations |
| Q37678908 | Medical Care of the Patient With Compensated Cirrhosis |
| Q44728654 | Membrane cholesterol modulates dihydropyridine receptor function in mice fetal skeletal muscle cells |
| Q57012269 | Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs |
| Q40274682 | Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes |
| Q37336662 | Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8 years follow up study |
| Q46123356 | Moderately increased protein intake predominately from egg sources does not influence whole body, regional, or muscle composition responses to resistance training in older people. |
| Q38991475 | Modulation of Systemic Metabolism by MMP-2: From MMP-2 Deficiency in Mice to MMP-2 Deficiency in Patients |
| Q37235648 | Molecular basis for statin-induced muscle toxicity: implications and possibilities |
| Q36958324 | Molecular mechanisms of statin intolerance |
| Q38807388 | Muscle rupture associated with statin use. |
| Q46909422 | Muscle symptoms associated with statins: a series of twenty patients |
| Q38250622 | Muscle- and skeletal-related side-effects of statins: tip of the iceberg? |
| Q27023343 | Muscular effects of statins in the elderly female: a review |
| Q45194187 | Myopathies under therapy with lipid-lowering agents |
| Q33815469 | Myopathy in Patients Taking Atorvastatin: A Pilot Study |
| Q37563958 | Myopathy with statin-fibrate combination therapy: clinical considerations |
| Q40731309 | Neuromuscular Effects of Rocuronium Bromide in Patients in Statin Therapy for at least Three Months |
| Q36232361 | New insights in the treatment of dyslipidemia: a focus on cardiovascular event reduction and the anti-atherosclerotic effects of atorvastatin |
| Q28299261 | Niacin extended-release/simvastatin |
| Q27002774 | Niacin, an old drug with a new twist |
| Q43661914 | No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy |
| Q38272551 | Non-traditional dosing of statins in statin-intolerant patients-is it worth a try? |
| Q54967977 | Novel Phenoxazinones as potent agonist of PPAR-α: design, synthesis, molecular docking and in vivo studies. |
| Q42930518 | Novel pyrrole- and 1,2,3-triazole-based 2,3-oxidosqualene cyclase inhibitors |
| Q38087150 | Nutrition management of amyotrophic lateral sclerosis |
| Q37489569 | OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis |
| Q47147374 | Ontology-based systematical representation and drug class effect analysis of package insert-reported adverse events associated with cardiovascular drugs used in China |
| Q36334689 | Optimising acid inhibition treatment. |
| Q46807616 | Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure in treating hyperlipidemia |
| Q36475343 | Overcoming 'ageism' bias in the treatment of hypercholesterolaemia : a review of safety issues with statins in the elderly |
| Q28073319 | Overcoming Challenges With Statin Therapy |
| Q36555257 | Overprescribing of lipid lowering agents |
| Q88160419 | Oxidative stress as a possible mechanism of statin-induced myopathy |
| Q38748829 | PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab |
| Q35138221 | Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone Hydrolysis |
| Q54488613 | Percutaneous lovastatin accelerates bone healing but is associated with periosseous soft tissue inflammation in a canine tibial osteotomy model. |
| Q38653570 | Peri-operative cardiac protection for non-cardiac surgery |
| Q38092149 | Perioperative statin therapy |
| Q36974672 | Pharmacogenetics and cardiovascular disease--implications for personalized medicine |
| Q47130405 | Pharmacogenetics in Cardiovascular Medicine |
| Q57302676 | Pharmacogenetics of Adverse Drug Reactions |
| Q34163351 | Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants |
| Q38510741 | Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders. |
| Q36335716 | Pharmacogenomics of cholesterol-lowering therapy |
| Q28079822 | Pharmacogenomics of statins: understanding susceptibility to adverse effects |
| Q34137575 | Pharmacogenomics: a systems approach |
| Q33375573 | Pharmacogenomics: candidate gene identification, functional validation and mechanisms |
| Q51305299 | Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents. |
| Q39015072 | Pharmacological management of diabetic dyslipidemia |
| Q36845662 | Physician utilization, risk-factor control, and CKD progression among participants in the Kidney Early Evaluation Program (KEEP). |
| Q46810895 | Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis |
| Q36055457 | Plasma metabolomic profiles enhance precision medicine for volunteers of normal health |
| Q42230722 | Plasmapheresis in a patient with rhabdomyolysis: a case report |
| Q64290036 | Potential Drug Interactions Forgotten |
| Q34571112 | Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment |
| Q80041547 | Preface |
| Q36327403 | Pregabalin and simvastatin: first report of a case of rhabdomyolysis |
| Q57312174 | Prevalence and risk factors of muscle complications secondary to statins |
| Q36841011 | Prevalence of musculoskeletal pain and statin use. |
| Q38099824 | Proximal myopathy: diagnostic approach and initial management |
| Q28542543 | RNA-sequencing analysis of HepG2 cells treated with atorvastatin |
| Q35946141 | Race, ethnicity, and sociocultural characteristics predict noncompliance with lipid-lowering medications |
| Q40703907 | Rare variants in known and novel candidate genes predisposing to statin-associated myopathy. |
| Q38113531 | Rational for statin use in psoriatic patients. |
| Q39212423 | Recommendations for Managing Drug-Drug Interactions with Statins and HIV Medications |
| Q50469720 | Red yeast rice and coenzyme Q10 as safe alternatives to surmount atorvastatin-induced myopathy in hyperlipidemic rats. |
| Q50579302 | Red yeast rice for dyslipidemia in statin-intolerant patients. |
| Q36139708 | Reduced knee extensor function in heart failure is not explained by inactivity |
| Q43958567 | Relationships between HMG-CoA reductase inhibitors (statin) use and strength, balance and falls in older people |
| Q38044467 | Review: immune-mediated necrotizing myopathies--a heterogeneous group of diseases with specific myopathological features |
| Q81382814 | Rhabdomyolysis |
| Q48236535 | Rhabdomyolysis after co-administration of a statin and fusidic acid: an analysis of the literature and of the WHO database of adverse drug reactions |
| Q37410211 | Rhabdomyolysis and acute kidney injury associated with hypothyroidism and statin therapy |
| Q35782066 | Rhabdomyolysis and exercise-associated hyponatremia in ultra-bikers and ultra-runners |
| Q28166923 | Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy |
| Q28306610 | Rhabdomyolysis associated with the nutritional supplement Hydroxycut |
| Q44929068 | Rhabdomyolysis caused by Commiphora mukul, a natural lipid-lowering agent |
| Q42912871 | Rhabdomyolysis due to the additive effect of statin therapy and hypothyroidism: a case report |
| Q41544748 | Rhabdomyolysis in a Patient with Severe Hypothyroidism. |
| Q92310963 | Rhabdomyolysis in a Young Patient due to Hypothyroidism without Any Precipitating Factor |
| Q45206650 | Rhabdomyolysis in a patient receiving atorvastatin and fluconazole |
| Q28168134 | Rhabdomyolysis in association with simvastatin and amiodarone |
| Q42704777 | Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin |
| Q33507272 | Rhabdomyolysis in community acquired bacterial sepsis--a retrospective cohort study |
| Q36954132 | Rhabdomyolysis induced acute renal failure secondary to statins |
| Q46594713 | Rhabdomyolysis induced by simvastatin-fluconazole combination |
| Q36856634 | Rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasone |
| Q44970021 | Rhabdomyolysis triggered by cytomegalovirus infection in a heart transplant patient on concomitant cyclosporine and atorvastatin therapy |
| Q34526546 | Rhabdomyolysis with simvastatin |
| Q50027469 | Rhabdomyolysis: a rare complication of Hashimoto's thyroiditis precipitated by statin therapy. |
| Q28087634 | Rhabdomyolysis: pathogenesis, diagnosis, and treatment |
| Q37693135 | Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. |
| Q79296519 | Risk factors for rhabdomyolysis with simvastatin and atorvastatin |
| Q90131873 | Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study |
| Q35904825 | Role of fibric acid derivatives in the management of risk factors for coronary heart disease |
| Q46686112 | Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity |
| Q41066037 | Rosuvastatin (Crestor) and rhabdomyolysis |
| Q24594814 | Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective |
| Q46686080 | Rosuvastatin: characterization of induced myopathy in the rat. |
| Q34579035 | SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers |
| Q53099880 | SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. |
| Q38164683 | Safety and efficacy of statins in patients with end-stage renal disease |
| Q57816047 | Safety assessment of concurrent statin treatment and evaluation of drug interactions in China |
| Q38541832 | Safety considerations with fenofibrate/simvastatin combination. |
| Q36766127 | Safety of 50,000-100,000 Units of Vitamin D3/Week in Vitamin D-Deficient, Hypercholesterolemic Patients with Reversible Statin Intolerance |
| Q44583582 | Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients |
| Q46874040 | Safety of statins when response is carefully monitored: a study of 336 heart recipients |
| Q33949312 | Safety of statins: an update |
| Q38041209 | Second line options for hyperlipidemia management after cardiac transplantation. |
| Q38248457 | Secondary prevention of stroke in the elderly: focus on drug therapy |
| Q37582800 | Secondary prevention strategies for coronary heart disease |
| Q37087367 | Secondary stroke prevention strategies for the oldest patients: possibilities and challenges |
| Q34306372 | Selected statins produce rapid spinal motor neuron loss in vitro. |
| Q34306983 | Selenoprotein synthesis and side-effects of statins |
| Q43227855 | Session 4: CVD, diabetes and cancer: A dietary portfolio for management and prevention of heart disease |
| Q37575362 | Severe Rhabdomyolysis as Complication of Interaction between Atorvastatin and Fusidic Acid in a Patient in Lifelong Antibiotic Prophylaxis: A Dangerous Combination. |
| Q36897401 | Severe obstructive sleep apnea after cerivastatin therapy: a case report |
| Q46045883 | Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient. |
| Q39455540 | Severe rhabdomyolysis associated with simvastatin and role of ciprofloxacin and amlodipine coadministration |
| Q37201803 | Severe vitamin d deficiency, myopathy, and rhabdomyolysis |
| Q35673800 | Should the insulin resistance syndrome be treated in the elderly? |
| Q37197698 | Simultaneous Bilateral Carotid Stenting for Symptomatic Bilateral High-Grade Carotid Stenosis: A Retrospective Clinical Investigation |
| Q35707959 | Simultaneous determination of coenzyme Q10, cholesterol, and major cholesterylesters in human blood plasma |
| Q48347873 | Simvastatin activates single skeletal RyR1 channels but exerts more complex regulation of the cardiac RyR2 isoform. |
| Q43699737 | Simvastatin alters fibroblastic cell responses involved in tissue repair |
| Q35855311 | Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes |
| Q41860525 | Simvastatin inhibits glucose metabolism and legumain activity in human myotubes |
| Q89642081 | Simvastatin intolerance genetic determinants: some features in ethnic Uzbek patients with coronary artery disease |
| Q90345876 | Simvastatin nanoliposome induces myocardial and hepatic toxicities due to its absorption enhancement in mice |
| Q34718197 | Simvastatin represses protein synthesis in the muscle-derived C₂C₁₂ cell line with a concomitant reduction in eukaryotic initiation factor 2B expression |
| Q48122911 | Simvastatin-associated dermatomyositis. |
| Q42067292 | Simvastatin-induced dermatomyositis in a 50-year-old man. |
| Q41086545 | Simvastatin-induced myoglobinuric acute kidney injury following ciclosporin treatment for alopecia universalis |
| Q37872364 | Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition |
| Q50955893 | Single intra-articular injection of fluvastatin-PLGA microspheres reduces cartilage degradation in rabbits with experimental osteoarthritis. |
| Q50691921 | Skeletal muscle susceptibility to clofibrate induction of lesions in rats. |
| Q36355588 | Skeletal muscle ultrastructure and function in statin-tolerant individuals |
| Q37677201 | Soy milk versus simvastatin for preventing atherosclerosis and left ventricle remodeling in LDL receptor knockout mice |
| Q38963276 | Squalene synthase induces tumor necrosis factor receptor 1 enrichment in lipid rafts to promote lung cancer metastasis |
| Q33666411 | Statin Induced Rhabdomyolysis with Non Oliguric Renal Failure: A Rare Presentation |
| Q35245459 | Statin Intolerance Because of Myalgia, Myositis, Myopathy, or Myonecrosis Can in Most Cases be Safely Resolved by Vitamin D Supplementation |
| Q40321293 | Statin Use and the Risk of Type 2 Diabetes Mellitus in Children and Adolescents |
| Q34292468 | Statin drug interactions and related adverse reactions |
| Q48145497 | Statin drug interactions and related adverse reactions: an update |
| Q33692765 | Statin induced myopathy presenting as mechanical musculoskeletal pain observed in two chiropractic patients |
| Q30245218 | Statin intolerance - a question of definition |
| Q35232279 | Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel |
| Q38757732 | Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else? |
| Q37119387 | Statin myopathy |
| Q46900599 | Statin myopathy: incidence, risk factors, and pathophysiology |
| Q37855316 | Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators |
| Q33947257 | Statin therapy and the expression of genes that regulate calcium homeostasis and membrane repair in skeletal muscle |
| Q38808558 | Statin therapy in cardiac allograft vasculopathy progression in heart transplant patients: Does potency matter? |
| Q37765064 | Statin therapy--Part II: Clinical considerations for cardiovascular disease |
| Q36508082 | Statin use and cancer risk: an epidemiologic review |
| Q35697228 | Statin use and musculoskeletal pain among adults with and without arthritis |
| Q36582678 | Statin withdrawal: clinical implications and molecular mechanisms |
| Q38863086 | Statin-Associated Myopathy in a Pediatric Preventive Cardiology Practice |
| Q36509301 | Statin-associated muscle-related adverse effects: a case series of 354 patients |
| Q41825872 | Statin-associated polymyositis following omeprazole treatment. |
| Q92876245 | Statin-dependent modulation of mitochondrial metabolism in cancer cells is independent of cholesterol content |
| Q46599849 | Statin-disclosed acid maltase deficiency |
| Q37323835 | Statin-induced Myopathy |
| Q28086884 | Statin-induced Myopathy in Skeletal Muscle: the Role of Exercise |
| Q37326940 | Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect |
| Q44739535 | Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relatives |
| Q37946182 | Statin-induced myopathies |
| Q37253606 | Statin-induced myopathy in a usual care setting-a prospective observational study of gender differences |
| Q34554637 | Statin-induced myopathy: the two faces of Janus |
| Q33551640 | Statin-induced rhabdomyolysis: a comprehensive review of case reports |
| Q37578459 | Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety |
| Q34699345 | Statins and dietary and serum cholesterol are associated with increased lean mass following resistance training |
| Q39883450 | Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression |
| Q36079406 | Statins and hepatotoxicity: focus on patients with fatty liver |
| Q43215640 | Statins and modulation of oxidative stress. |
| Q34635121 | Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation |
| Q35217933 | Statins and safety: applying the results of randomized trials to clinical practice |
| Q37382024 | Statins and succinylcholine interaction: A cause of concern for serious muscular damage in anesthesiology practice! |
| Q38286231 | Statins and the neuromuscular system: a neurologist's perspective |
| Q33949348 | Statins and their interactions with other lipid-modifying medications: safety issues in the elderly |
| Q39420246 | Statins cause profound effects on gene expression in human cancer cells in vitro: the role of membrane microdomains. |
| Q90090917 | Statins for primary prevention of cardiovascular disease and the risk of acute kidney injury |
| Q48168019 | Statins in nonsurgical and surgical periodontal therapy. A systematic review and meta-analysis of preclinical in vivo trials |
| Q42758890 | Statins, lack of energy and ubiquinone |
| Q84770396 | Statins: a case for drug withdrawal in patients with dementia |
| Q35827103 | Suboptimal choices and dosing of statins at start of therapy |
| Q37701534 | Support of drug therapy using functional foods and dietary supplements: focus on statin therapy |
| Q36921041 | Surveillance and treatment of dyslipidemia in the post-infarct patient: can a nurse-led management approach make a difference? |
| Q58584433 | The Mevalonate Pathway Is Indispensable for Adipocyte Survival |
| Q33440652 | The Pathway Less Traveled: Moving from Candidate Genes to Candidate Pathways in the Analysis of Genome-Wide Data from Large Scale Pharmacogenetic Association Studies |
| Q39345884 | The Risk of Achilles or Biceps Tendon Rupture in New Statin Users: A Propensity Score-Matched Sequential Cohort Study |
| Q41516471 | The adjuvant value of Herba Cistanches when used in combination with statin in murine models. |
| Q90089701 | The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease |
| Q83136408 | The battle to keep or lose skeletal muscle with ageing |
| Q36515517 | The case for more intensive use of statins |
| Q34216710 | The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. |
| Q34276618 | The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. |
| Q81578231 | The clinical use of macro and surface electromyography in diagnosis and follow-up of endocrine and drug-induced myopathies |
| Q38089090 | The controversy of a wider statin utilization: why? |
| Q34559582 | The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications |
| Q43003337 | The effect of acute administration of rifampicin and imatinib on the enterohepatic transport of rosuvastatin in vivo |
| Q89687364 | The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials |
| Q47962524 | The effects of 2 weeks of statin treatment on mitochondrial respiratory capacity in middle-aged males: the LIFESTAT study. |
| Q38228143 | The effects of statin medications on aerobic exercise capacity and training adaptations. |
| Q37999089 | The emerging role of plasma lipidomics in cardiovascular drug discovery |
| Q35223989 | The epidemiology of sarcopenia in community living older adults: what role does lifestyle play? |
| Q42494853 | The mevalonate pathway as a metabolic requirement for autophagy-implications for growth control, proteostasis, and disease |
| Q24681859 | The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity |
| Q42017460 | The pleotropic role of statins: Could it be the imminent host modulation agent in periodontics? |
| Q34948312 | The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials |
| Q35692031 | The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy |
| Q37808130 | The role of red yeast rice for the physician |
| Q42721442 | The role of vitamin D and SLCO1B1*5 gene polymorphism in statin-associated myalgias |
| Q38742876 | The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia |
| Q34636135 | The safety of statins in clinical practice |
| Q43064741 | The use of statins potentiates the insulin-sensitizing effect of exercise training in obese males with and without Type 2 diabetes |
| Q53079943 | Ticagrelor-induced acute kidney injury can increase serum concentration of statin and lead to concurrence of rhabdomyolysis. |
| Q33770940 | Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial |
| Q88868156 | Towards a More Personalized Treatment of Dyslipidemias to Prevent Cardiovascular Disease |
| Q38089842 | Towards companion diagnostics for the management of statin therapy |
| Q82029922 | Toxic and iatrogenic myopathies |
| Q35197131 | Toxicity of antilipidemic agents: facts and fictions |
| Q38188290 | Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies. |
| Q27006481 | Treatment of dyslipidemia with statins and physical exercises: recent findings of skeletal muscle responses |
| Q34259182 | Ultrasound diagnosis of bilateral quadriceps tendon rupture after statin use |
| Q41375965 | Uncover the Underlying Mechanism of Drug-Induced Myopathy by Using Systems Biology Approaches. |
| Q34172967 | Underappreciated statin-induced myopathic weakness causes disability |
| Q33867311 | Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database |
| Q26741705 | Unmet Needs in LDL-C Lowering: When Statins Won't Do! |
| Q37942033 | Update on toxic myopathies |
| Q37172286 | Use of an electronic medical record to characterize cases of intermediate statin-induced muscle toxicity |
| Q92211885 | Vaccine Against PCSK9 Improved Renal Fibrosis by Regulating Fatty Acid β-Oxidation |
| Q58762710 | Vascular Protective Effects of Leaf Extract on Postmenopausal Rats Fed with Thermoxidized Palm Oil Diet: Evidence at Microscopic Level |
| Q37725879 | Whole genome association studies in complex diseases: where do we stand? |
| Q79788888 | [Autoimmune diseases and statins] |
| Q83022125 | [Medically induced myopathia] |
| Q89412469 | [Weakness of the extremities in a 73-year-old male patient] |
Search more.